SG11201600076WA - LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME - Google Patents

LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

Info

Publication number
SG11201600076WA
SG11201600076WA SG11201600076WA SG11201600076WA SG11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA
Authority
SG
Singapore
Prior art keywords
sirna
double
preventing
composition
same
Prior art date
Application number
SG11201600076WA
Other languages
English (en)
Inventor
Jeiwook Chae
Han Oh Park
Pyoung Oh Yoon
Boram Han
Han-Na Kim
Sung-Il Yun
Jun Hong Park
Youngho Ko
Gi-Eun Choi
Junsoo Jung
Jae Eun Kim
Original Assignee
Bioneer Corp
Sanofi Aventis Korea Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp, Sanofi Aventis Korea Co Ltd filed Critical Bioneer Corp
Publication of SG11201600076WA publication Critical patent/SG11201600076WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201600076WA 2013-07-09 2014-07-09 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME SG11201600076WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130080579A KR20150006742A (ko) 2013-07-09 2013-07-09 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
PCT/KR2014/006145 WO2015005669A1 (en) 2013-07-09 2014-07-09 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

Publications (1)

Publication Number Publication Date
SG11201600076WA true SG11201600076WA (en) 2016-02-26

Family

ID=52280271

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600076WA SG11201600076WA (en) 2013-07-09 2014-07-09 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

Country Status (7)

Country Link
US (1) US20160168573A1 (enrdf_load_stackoverflow)
EP (1) EP3019611A4 (enrdf_load_stackoverflow)
JP (1) JP2016531563A (enrdf_load_stackoverflow)
KR (1) KR20150006742A (enrdf_load_stackoverflow)
CN (1) CN105765069A (enrdf_load_stackoverflow)
SG (1) SG11201600076WA (enrdf_load_stackoverflow)
WO (1) WO2015005669A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116236501A (zh) * 2017-07-28 2023-06-09 雷莫内克斯生物制药有限公司 用于预防或治疗肝癌的药物组合物
CN110964816A (zh) * 2019-11-20 2020-04-07 深圳市鲲鹏未来科技有限公司 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法
CN111189808B (zh) * 2019-12-25 2022-12-06 宁夏医科大学总医院 与肝脏损伤、肝细胞凋亡相关特异蛋白分子标志物筛选方法
CN111596059A (zh) * 2020-05-19 2020-08-28 上海长海医院 Gankyrin蛋白作为新型分子标志物在前列腺癌预后评估中的应用
KR102329524B1 (ko) * 2021-08-06 2021-11-23 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
WO2023013818A1 (ko) * 2021-08-06 2023-02-09 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
CN120265772A (zh) * 2022-09-28 2025-07-04 俄亥俄州国家创新基金会 用于治疗癌症转移的rna复合物和纳米结构
CN117281792A (zh) * 2023-07-25 2023-12-26 浙江大学 一种用于增强肝癌免疫疗法治疗效果的纳米制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159626C (en) * 1993-04-02 2001-10-02 Lingna Li Method for delivering beneficial compositions to hair follicles
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
AU2005292083A1 (en) * 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
WO2008087643A2 (en) * 2007-01-16 2008-07-24 Proteologics Ltd Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
KR101224828B1 (ko) * 2009-05-14 2013-01-22 (주)바이오니아 siRNA 접합체 및 그 제조방법
EP2496268A4 (en) * 2009-11-06 2013-06-19 Univ Chung Ang Ind GENERATING SYSTEMS ON NANOPARTICLE BASIS
RU2599449C1 (ru) * 2011-12-15 2016-10-10 Байонир Корпорейшн Новые конъюгаты олигонуклеотидов и их применение

Also Published As

Publication number Publication date
CN105765069A (zh) 2016-07-13
WO2015005669A1 (en) 2015-01-15
US20160168573A1 (en) 2016-06-16
JP2016531563A (ja) 2016-10-13
EP3019611A1 (en) 2016-05-18
EP3019611A4 (en) 2017-06-14
KR20150006742A (ko) 2015-01-19

Similar Documents

Publication Publication Date Title
SG11201600076WA (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
EP3019612A4 (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
EP3326661B8 (en) Bio-ink composition having improved physical and biological properties
IL243752A0 (en) Multispecific antibodies, preparations containing them and their uses
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
EP3060207A4 (en) Methods and compositions for treating cancer
IL241055A0 (en) Transgenic liver tissues, their arrays and methods for their preparation
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PL2986304T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
IL245839A0 (en) Inhibitors of rna polymerase i and use of preparations containing them for treatment
EP3018209A4 (en) Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease
IL277261A (en) Low molecular weight compounds for cancer treatment
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
EP3085784A4 (en) Nucleic acid inducing rna interference modified for preventing off-target, and use thereof
PT3272874T (pt) Composição de reagente para biossensor e biossensor tendo a mesma
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
EP3077049A4 (en) Compositions and methods for treating vitiligo
EP3085380A4 (en) Composition for treating prostate cancer
ZA202001649B (en) Rna molecules
EP3052122A4 (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
EP2981554A4 (en) Methods and compositions for treating and preventing disease associated with avb8 integrin
HK1225630A1 (zh) 小分子c-myc抑制劑
BR112015002729A2 (pt) composição de revestimento, artigo, e, método.
IL258642B (en) Anti-cd43 antibody and its use for cancer treatment
EP3020399A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER